share_log

Exicure | 8-K: Exicure, Inc. Reports Third Quarter 2023 Financial Results

Exicure | 8-K: Exicure, Inc. Reports Third Quarter 2023 Financial Results

Exicure | 8-K：Exicure, Inc. 公佈2023年第三季度財務業績
美股sec公告 ·  05/16 16:52
Moomoo AI 已提取核心訊息
On May 16, 2024, Exicure, Inc., a biotechnology company historically focused on nucleic acid therapies, reported its financial results for the third quarter ended September 30, 2023. The company disclosed a significant decrease in cash and cash equivalents, from $8.6 million at the end of 2022 to $0.9 million as of September 30, 2023, and further down to $0.2 million by April 30, 2024. Exicure highlighted the need for immediate additional funding to continue operations. Research and development expenses for the quarter were reported at $0, reflecting the cessation of all research and development activities following a restructuring announced in September 2022. General and administrative expenses remained relatively stable at $2.4 million. The net loss for the quarter was $5.3 million, a slight increase from the $5.2 million loss in the same period the previous year. The company's management expressed concerns about the ability to continue funding operations without substantial additional financing, which is needed imminently to pay expenses and explore strategic alternatives.
On May 16, 2024, Exicure, Inc., a biotechnology company historically focused on nucleic acid therapies, reported its financial results for the third quarter ended September 30, 2023. The company disclosed a significant decrease in cash and cash equivalents, from $8.6 million at the end of 2022 to $0.9 million as of September 30, 2023, and further down to $0.2 million by April 30, 2024. Exicure highlighted the need for immediate additional funding to continue operations. Research and development expenses for the quarter were reported at $0, reflecting the cessation of all research and development activities following a restructuring announced in September 2022. General and administrative expenses remained relatively stable at $2.4 million. The net loss for the quarter was $5.3 million, a slight increase from the $5.2 million loss in the same period the previous year. The company's management expressed concerns about the ability to continue funding operations without substantial additional financing, which is needed imminently to pay expenses and explore strategic alternatives.
2024年5月16日，歷史上專注於核酸療法的生物技術公司Exicure, Inc. 公佈了截至2023年9月30日的第三季度財務業績。該公司透露，現金及現金等價物大幅減少，從2022年底的860萬美元降至2023年9月30日的90萬美元，到2024年4月30日進一步下降至20萬美元。Exicure強調需要立即提供額外資金以繼續運營。該季度的研發費用報告爲0美元，這反映了2022年9月宣佈的重組後所有研發活動的停止。一般和行政費用保持相對穩定，爲240萬美元。該季度的淨虧損爲530萬美元，較去年同期的520萬美元虧損略有增加。該公司的管理層對在沒有大量額外融資的情況下繼續爲運營提供資金的能力表示擔憂，迫切需要這筆資金來支付費用和探索戰略替代方案。
2024年5月16日，歷史上專注於核酸療法的生物技術公司Exicure, Inc. 公佈了截至2023年9月30日的第三季度財務業績。該公司透露，現金及現金等價物大幅減少，從2022年底的860萬美元降至2023年9月30日的90萬美元，到2024年4月30日進一步下降至20萬美元。Exicure強調需要立即提供額外資金以繼續運營。該季度的研發費用報告爲0美元，這反映了2022年9月宣佈的重組後所有研發活動的停止。一般和行政費用保持相對穩定，爲240萬美元。該季度的淨虧損爲530萬美元，較去年同期的520萬美元虧損略有增加。該公司的管理層對在沒有大量額外融資的情況下繼續爲運營提供資金的能力表示擔憂，迫切需要這筆資金來支付費用和探索戰略替代方案。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息